VRCA实时信号 | 通过Getagraph.com最大化利润

购买 117671 min ago

@ $5.55

发出时间: 13 Feb 2024 @ 23:00

回报率: 30.93%

上一信号: Feb 10 - 00:12

上一信号: 出售

回报率: 2.31 %

Live Chart Being Loaded With Signals

Commentary (4 May 2024 @ 04:00):

Verrica Pharmaceuticals Inc., a dermatology therapeutics company, develops and commercializes treatments for people with skin diseases in the United States...

Stats
今日成交量	301 095
平均成交量	146 954
市值	307.97M
EPS	$0 ( 2024-02-29 )
下一个收益日期	( $-0.530 ) 2024-05-07
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-4.91
ATR14	$0.0180 (0.25%)

Insider Trading

Date	Person	Action	Amount	type
2024-03-15	Hayes Christopher G.	Buy	40 000	Common Stock
2024-03-15	Hayes Christopher G.	Buy	80 000	Employee Stock Option (right to buy)
2024-03-15	Goldenberg Gary	Buy	40 000	Common Stock
2024-03-15	Goldenberg Gary	Buy	80 000	Employee Stock Option (right to buy)
2024-03-15	Kohler Terry	Buy	80 000	Employee Stock Option (right to buy)

INSIDER POWER
90.88
Last 98 transactions
Buy: 14 420 498 \| Sell: 288 608

音量相关性

長: -0.04 (neutral)

短: 0.12 (neutral)

Signal:(56.071) Neutral

Verrica Pharmaceuticals 相关性

10 最正相关
TGTX	0.959
IDCC	0.956
SLMBP	0.955
VBOCU	0.955
RAM	0.95
WKEY	0.95
OVLY	0.948
NCAC	0.947
MESA	0.946
GPACU	0.945

10 最负相关
CBNK	-0.945
CYTO	-0.939
GSMG	-0.938
GNTY	-0.936
BFRI	-0.936
FGBI	-0.936
GOOD	-0.934
AMNB	-0.93
CMLS	-0.929
ALHC	-0.927

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

Verrica Pharmaceuticals 相关性 - 货币/商品

0.60
( weak )

-0.21
( neutral )

0.00
( neutral )

-0.34
( neutral )

-0.15
( neutral )

Verrica Pharmaceuticals 财务报表

Annual	2023
营收:	$5.12M
毛利润:	$3.96M (77.28 %)
EPS:	$-1.480

FY	2023
营收:	$5.12M
毛利润:	$3.96M (77.28 %)
EPS:	$-1.480

FY	2022
营收:	$9.03M
毛利润:	$8.31M (91.97 %)
EPS:	$-0.810

FY	2021
营收:	$12.00M
毛利润:	$12.00M (100.00 %)
EPS:	$-1.300

Financial Reports:

No articles found.

Verrica Pharmaceuticals

Verrica Pharmaceuticals Inc., a dermatology therapeutics company, develops and commercializes treatments for people with skin diseases in the United States. The company's lead product candidate includes VP-102 for the treatment of molluscum contagiosum; that has completed Phase II clinical trial for the treatment of external genital warts; and which is in Phase II clinical trial for treating common warts. It is also developing cantharidin-based product candidate, VP-103 for treating plantar warts. The company has a license and collaboration agreement with Torii Pharmaceutical Co., Ltd. for the development and commercialization of its product candidates for the treatment of molluscum contagiosum and common warts in Japan, including VP-102; and a license agreement with Lytix Biopharma AS to develop and commercialize LTX-315 for dermatological oncology indications. Verrica Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in West Chester, Pennsylvania.

实时更新： Verrica Pharmaceuticals [VRCA]

Upcoming Earnings Alert